India s Covaxin effectively neutralises Delta variant of Covid: US National Institute of Health
A health worker displays the empty vials of COVAXIN vaccine for COVID-19 (AP Photo)
AKIPRESS.COM - India’s Coronavirus vaccine Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the U.S National Institute of Health (NIH) has said, The Indian Express reported.
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively.
United-states
Kansas
India
United-kingdom
American
Bharat
Sunil-david
Anthonys-fauci
Us-national-institute-of-health
Indo-us-vaccine-action-program
National-institute-of-allergy
Adjuvant-development-program
India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US National Institute of Health has said. The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively. The top American health research institute, which has a history of strong scientific collaboration with India, also said that an adjuvant developed with funding from it has contributed to the success of the highly efficacious Covaxin, which has been administered to roughly 25 million people till date in India and elsewhere.
United-states
Kansas
India
Hyderabad
Andhra-pradesh
United-kingdom
New-delhi
Delhi
American
Bharat
Sunil-david
Anthonys-fauci
Covaxin has been administered to roughly 25 million people till date in India and elsewhere. (File)
Washington:
India s Covaxin, developed by Bharat Biotech in collaboration with the Indian Council of Medical Research, effectively neutralises both Alpha and Delta variants of coronavirus, the US National Institute of Health has said.
The NIH said results of two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralise the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the UK and India, respectively.
The top American health research institute, which has a history of strong scientific collaboration with India, also said that an adjuvant developed with funding from it has contributed to the success of the highly efficacious Covaxin, which has been administered to roughly 25 million people till date in India and elsewhere.
United-states
Kansas
India
Hyderabad
Andhra-pradesh
United-kingdom
New-delhi
Delhi
American
Bharat
Sunil-david
Delta-covid
Highlights
It quoted the results of two studies.
New Delhi: The National Institutes of Health (NIH), a part of the US Department of Health and Human Services, on Tuesday (June 29, 2021) said that Covaxin effectively neutralizes Alpha and Delta variants of COVID-19.
It quoted two studies and stated that they have found that the Covaxin coronavirus vaccine generates antibodies that neutralize the Alpha and Delta variants of COVID-19, first identified in the United Kingdom and India, respectively. Results from two studies of blood serum from people who had received Covaxin suggest that the vaccine generates antibodies that effectively neutralize the B.1.1.7 (Alpha) and B.1.617 (Delta) variants of SARS-CoV-2, first identified in the United Kingdom and India, respectively, the NIH said.
United-states
Kansas
Hyderabad
Andhra-pradesh
India
United-kingdom
New-delhi
Delhi
Bharat
Anthony-fauci
National-institute-of-allergy
Human-services
vimarsana © 2020. All Rights Reserved.